Kanghong Pharmaceuticals: Eight drugs selected for the national centralized drug procurement list.

Kanghong Pharmaceutical announced that the company has participated in the national centralized drug procurement agreement period to continue the purchase tender work. Guaifenesin mosapride tablets, rizatriptan tablets, and eight other products were selected in the purchasing results list and supply list. This centralized procurement will be implemented from March 2026 and will end on December 31, 2028. Among them, quetiapine fumarate tablets and sodium hyaluronate eye drops are participating in the centralized procurement continuation work for the first time, which will enrich the company's product line. However, the signing of product procurement contracts and the implementation of market sales are still uncertain, and the company will follow up and disclose in a timely manner.